Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 8/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749580 | 0.84 | KDM5A (0.50) | PBKALDH1A1CYP3A4CYP3A5CAMKK2 | |
| SCHEMBL18225726 | 0.82 | PBK (0.44) | PBKALDH1A1CYP3A4CYP3A5 | |
| SCHEMBL2005978 | 0.82 | PBK (0.50) | PBKALDH1A1CYP3A4CYP3A5CAMKK2 | |
| SCHEMBL18225106 | 0.78 | PBK (0.50) | PBKALDH1A1CYP3A4CYP3A5 | |
| SCHEMBL18225384 | 0.73 | CYP3A4 (0.61) | PBKCYP3A4CYP3A5 | |
| SCHEMBL18248945 | 0.72 | PBK (0.42) | PBKALDH1A1CYP3A4CYP3A5 | |
| SCHEMBL18248944 | 0.72 | PBK (0.42) | PBKALDH1A1CYP3A4CYP3A5 | |
| SCHEMBL18248915 | 0.71 | EGFR (0.47) | PBKALDH1A1CYP3A4CYP3A5 | |
| SCHEMBL18224773 | 0.71 | CYP3A4 (0.55) | PBKCYP3A4CYP3A5 | |
| SCHEMBL18224844 | 0.71 | CYP3A4 (0.64) | PBKCYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | PBK 4051/4885ALDH1A1 2782/4885CYP3A4 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.